What is the appropriate inpatient management for a patient with acute on chronic kidney injury, anemia, and decompensated heart failure presenting with low hemoglobin, reduced estimated glomerular filtration rate, metabolic acidosis, elevated N‑terminal pro‑brain natriuretic peptide, and abnormal liver enzymes?

Management of Acute-on-Chronic Kidney Injury with Decompensated Heart Failure and Anemia

This patient requires immediate daily monitoring of volume status, renal function, and electrolytes with intravenous loop diuretics as the cornerstone of therapy, while carefully evaluating and treating the underlying anemia and temporarily withholding or reducing nephrotoxic medications including spironolactone given the severe renal dysfunction (eGFR 25, Cr 2.08). 1

Immediate Priorities

Volume Management and Diuretic Strategy

Given the elevated NT-proBNP (3786) indicating significant volume overload and decompensated heart failure, initiate intravenous loop diuretics immediately 1. The patient's eGFR of 25 mL/min mandates loop diuretics rather than thiazides as monotherapy 2.

Specific diuretic approach:

• Start with at least 40-80 mg IV furosemide (or equivalent oral dose if previously on diuretics) 3
• If inadequate response to bolus dosing (>240 mg/day), switch to continuous IV furosemide infusion, which is more effective in patients with worsening renal function 1
• Consider adding metolazone or thiazide diuretic synergistically with loop diuretics for refractory volume overload 2, 1
• Monitor daily: body weight, urine output, blood pressure, serum electrolytes, and renal function 1

Critical Medication Review

Immediately assess and adjust renin-angiotensin-aldosterone system (RAAS) inhibitors:

With Cr 2.08 (>250 μmol/L represents severe dysfunction), temporarily withhold or significantly reduce ACE inhibitors, ARBs, and spironolactone 1. The guideline explicitly states routine use is not recommended with creatinine >250 μmol/L due to lack of efficacy evidence and safety concerns 1.

Spironolactone must be temporarily withheld given the acute kidney injury risk and potential for hyperkalemia 1. Recheck electrolytes within 2-4 weeks if diuretics are reduced 1.

Stop all NSAIDs immediately if being used 2, 1.

Anemia Management

The hemoglobin of 9.6 g/dL (96 g/L) with elevated RDW suggests significant anemia contributing to heart failure symptoms.

Comprehensive anemia workup required 1:

• Evaluate for chronic blood loss, inflammatory illness
• Check iron studies, vitamin B12, and folate levels
• Treat any identified substrate deficiencies (iron, B12, folate) immediately 1

Transfusion consideration: While hemoglobin <90 g/L is associated with increased heart failure symptoms 1, this patient at 96 g/L falls in a gray zone. Consider blood transfusion if advanced symptoms persist after substrate deficiency correction 1. The evidence does not support aggressive erythropoietin use for mortality benefit 1.

Metabolic Acidosis Correction

The CO2 of 18 (low) with anion gap of 15 indicates metabolic acidosis, likely multifactorial from renal dysfunction and poor perfusion.

Address through:

• Improved renal perfusion via volume optimization
• Correction of underlying kidney injury
• Avoid aggressive bicarbonate replacement unless severe (pH <7.2) as this may worsen volume overload

Daily Monitoring Protocol

Mandatory daily assessments 1:

• Body weight
• Urine output (watch for oliguria)
• Blood pressure
• Serum electrolytes (sodium, potassium)
• Renal function (BUN, creatinine)
• Volume status examination (JVP, peripheral edema, lung crackles)

Acute renal dysfunction is defined as creatinine increase >30% from baseline 1. This patient's creatinine of 2.08 requires close surveillance.

Elevated Liver Enzymes

The markedly elevated transaminases (ALT 150, AST 265) and alkaline phosphatase (208) suggest hepatic congestion from right-sided heart failure or hypoperfusion injury.

Management:

• These typically improve with decongestion and improved cardiac output
• Rule out acute hepatic ischemia if hemodynamically unstable
• Monitor trend with diuresis

Advanced Therapies for Refractory Cases

If the patient fails to respond to high-dose IV loop diuretics (>240 mg/day):

Consider in highly selected cases under experienced supervision 1, 4:

• Continuous venovenous hemofiltration (CVVH) for severe renal insufficiency with refractory volume overload 1, 4
• Hypertonic saline combined with high-dose loop diuretics 1
• These require ICU-level monitoring

Beta-Blocker Initiation

Once clinically stable (euvolemic, adequate perfusion), initiate beta-blocker therapy before hospital discharge 1. Do not wait until outpatient follow-up. Patients started on beta-blockers during hospitalization have better long-term adherence and outcomes 1.

Common Pitfalls to Avoid

• Do not continue spironolactone with severe renal dysfunction and acute decompensation—hyperkalemia risk is substantial 1
• Do not use thiazides alone with eGFR <30 mL/min; only synergistically with loop diuretics 2
• Do not aggressively correct anemia with erythropoietin without addressing substrate deficiencies first—thrombotic risk exists 1
• Do not delay switching to continuous furosemide infusion if bolus therapy fails—this is more effective in worsening renal function 1
• Avoid excessive diuresis causing hypotension and further renal hypoperfusion 2

Recheck Timing

• Electrolytes and creatinine: within 1-3 days given advanced heart failure 1
• After each diuretic dose adjustment: within 7 days 1
• If RAAS inhibitors reduced: recheck potassium in 2-4 weeks 1